Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Shares Issued (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Shares Issued for 8 consecutive years, with $375000.0 as the latest value for Q1 2026.

  • Quarterly Shares Issued rose 69.68% to $375000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Feb 2026, down 99.04% year-over-year, with the annual reading at $1.7 million for FY2025, 22.56% down from the prior year.
  • Shares Issued for Q1 2026 was $375000.0 at Nurix Therapeutics, up from -$578000.0 in the prior quarter.
  • The five-year high for Shares Issued was $95.4 million in Q4 2024, with the low at -$578000.0 in Q4 2025.
  • Average Shares Issued over 5 years is $12.0 million, with a median of $399500.0 recorded in 2022.
  • The sharpest move saw Shares Issued surged 200700.0% in 2024, then crashed 100.61% in 2025.
  • Over 5 years, Shares Issued stood at $48000.0 in 2022, then soared by 1958.33% to $988000.0 in 2023, then surged by 9555.87% to $95.4 million in 2024, then plummeted by 100.61% to -$578000.0 in 2025, then surged by 164.88% to $375000.0 in 2026.
  • According to Business Quant data, Shares Issued over the past three periods came in at $375000.0, -$578000.0, and $977000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.